Because antibody production does not usually begin in a previously unsensitized mother until after delivery, erythroblastosis in subsequent children can be prevented by giving the mother an injection of Rhogam within 72 hours of delivery.
In the United States, about 40 to 60 percent of all adults in the middle- and upper-socioeconomic classes show antibody proof of prior infection with CMV; antibody proof is as high as 80 percent in adults in the lower socioeconomic class.
If mononucleosis is suspected, a physician will typically conduct a physical examination, including a "Monospot" antibody blood test that can indicate the presence of proteins or antibodies produced in response to infection with the EBV.
As of 2004 no specific treatment cured common variable immunodeficiency; each child is treated according to the individual clinical condition, the symptoms presented, and the antibody subclasses shown to be absent or deficient.
Therefore, all mothers who have Rh-negative blood and no apparent sensitization (as indicated by antibody titer) should be treated with a standard 300g dose of Rh(D) immune globulin (Rhogam) at about 28 weeks of gestation.